CAS 2052130-80-8

H3B-6545

CAS: 2052130-80-8

H3B-6545

Fórmula: C₃₀H₂₉F₄N₅O₂

Pureza: 98.87%

Peso molecular: 567.58

Ref: 54-PC1032850

H3B-6545

CAS: 2052130-80-8

Pureza: 98.87%

Ref: IN-DA01JODK

H3B-6545

CAS: 2052130-80-8

H3B-6545 is an investigational drug that is a CDK4/6 inhibitor. H3B-6545 has been shown to inhibit the growth of breast cancer cells in preclinical studies. The mechanism by which H3B-6545 inhibits breast cancer cell growth is not fully understood, but it appears to be related to its ability to inhibit aromatase activity and affect the expression of epidermal growth factor receptor (EGFR). The efficacy of H3B-6545 in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who have progressed following endocrine therapy or chemotherapy is currently being evaluated in a multicenter phase II study. H3B-6545 has also been shown to cause DNA mutations in vitro.

Fórmula: C₃₀H₂₉F₄N₅O₂

Pureza: Min. 95%

Peso molecular: 567.6 g/mol

Ref: 3D-CHD13080

H3B-6545

CAS: 2052130-80-8

H3B-6545 is a selective and oral estrogen receptor covalent antagonist (SERCA) used in the research of metastatic ER-positive, HER2-negative breast cancer.

Fórmula: C₃₀H₂₉F₄N₅O₂

Forma y color: Solid

Peso molecular: 567.58

Ref: TM-T11530L